[The effect of HBs-antigenemia on the clinical course of rheumatoid arthritis].

Our observations suggest that HBs-antigenemia may play a part in the heterogeneity of rheumatoid arthritis. This is manifested by some particular features of its clinical course, by disordered immunological reactivity, the functional state of the immunity B-system in particular. The greatest benefit from antirheumatic therapy occurred in those patients who received reaferon as part of their therapeutic programme.